Corona Crisis : who will win the vaccine competition?

Coronavirus is originated from Wuhan, China. It is known to all. From there the prevalent took shape and the virus has now spread all over the world. Five months have already passed. In the last five months, about 90 vaccines have been developed worldwide to fight against the virus. These vaccines are being monitored at various phases. In addition, almost every week, the world is coming up with new vaccines to deter this virus. At least six of these vaccines have been reported to be effective for the human body. In this situation, vaccine developers, financiers and other partners face a major challenge. Of all the vaccines that have been made in these five months, which one is actually powerful or which one is the most effective for the human body? This is the big challenge right now.
Corona Crisis : who will win the vaccine competition?

According to a report by Nature.com, thousands of people are involved in making a vaccine or a placebo. This process lasts from a few months to several years. Scientists continue to test the effects of this vaccine. However, at the time of this epidemic, scientists are rapidly continuing this process. Only vaccines against the virus can increase the body's immunity to fight the virus.
About 33 lakh 43 thousand coronavirus patients have been identified in the world so far. This number is increasing.
The World Health Organization (WHO) said in Geneva last April that it was planning several vaccine clinical trials. A number of developers and financiers are also planning to test the effectiveness of the vaccine on their own initiative. However, the main question that arises now is which vaccine will be tested by the first test and how will the effectiveness of that vaccine be compared and measured?
Corona Crisis : who will win the vaccine competition?

Mark Feinberg, president and chief executive of the New York-based International AIDS Vaccine Initiative (IAVI), said the development of an effective coronavirus vaccine requires a level of coordination and collaboration among all that has never happened before. In addition, we have to set a deadline that has never been imagined before.

Seth Berkeley, chief executive of The Vaccine Alliance-Gavi, an organization that finances immunization in low- and middle-income countries, said there was no way to get 200 vaccines in any way to test effectiveness.

The WHO's proposal is to work together to verify the effectiveness of the vaccine. The vaccine will be tested regularly step by step. Participants must first be enrolled for their vaccine test. Vaccines that do not seem to be working will be discarded there.

Marie-Paule Kieny, research director at the French National Institute of Health and Medical Research in Paris, said the WHO needed to first plan and detail how to measure the effectiveness of a vaccine. The overall approach needs to be planned. The biggest challenge is choosing which vaccine to test first.

Mark Feinberg said the WHO has set up an expert panel to decide on the basis of which vaccine will be tested first. In this case, strategic coordination is very important. Otherwise, chaos will ensue and all plans will be ruined. However, it seems that the WHO's single plan for vaccine testing is not enough.

In April, The US National Institutes of Health (NIH) began working in partnership with dozens of companies, including Bethesda, a technology company in Maryland, to develop drugs and vaccines for coronavirus. The Coalition of Epidemic Preparedness (CEPI) finances the development of vaccines worldwide. The company is helping to make nine vaccines again.

Melanie Saville, the agency's director of vaccine research and development, said they were considering spending about 2 billion on coronavirus vaccine efficacy testing, production and other costs.
Corona Crisis : who will win the vaccine competition?

Marie-Paule Kieny said vaccines that have been shown to boost immunity in humans and animals in the early stages of testing, and those that have the ability to produce them should be put forward to test the effectiveness of the vaccine. There are still some vaccines that have not been tested in humans. They have to be kept at the bottom.

Meanwhile, Andrew Pollard, an infectious disease researcher at Oxford University, said in an online press briefing that a vaccine was being developed at Oxford University's Jenner Institute. The vaccine is in the early stages of testing. The final effectiveness of the vaccine is likely to be tested in the next few months.

Swati Gupta, vice-president of IAVI and head of Emerging Infectious Diseases and Scientific Strategy, said developers must try to understand how to decide before comparing vaccines and comparing them with one another. Before testing, they need to make sure their vaccines are effective.
Shirley Weller, head of vaccines at the Welcome Trust Biomedical Charity in London, said comparative testing of one vaccine after another was crucial. Because developers basically work with vaccines with commercial models in mind. Such a model will not work in the current situation in the world.

Marie-Paule Kieny said the global demand for the coronavirus vaccine at the moment could help make developers more sincere and interested. In fact, we need more than one vaccine. Because a monopoly is always bad. In addition, the specified vaccine may not have sufficient production capacity.

Most experts say the coronavirus vaccine is being tested and tested to see if it is safe and effective for humans. However, some developers are testing the effectiveness of their vaccines in alternative ways.
Initially, the vaccine was tested in hundreds of people.

If a positive result is found, the vaccine regulator must seek permission from the vaccine regulator to apply it on an emergency basis, especially to health workers infected with the virus. Vaccine regulatory bodies such as the US Food and Drug Administration may allow it to be applied in case of emergency.

A spokesman for Cansino Biologics in Tianjin, China, said their company had developed such a vaccine. It can be applied in case of emergency.

But Catherine O'Brien, head of the WHO's Department of Immunizations, Vaccines and Biologicals, said no vaccine had been administered on an emergency basis at the moment. Only if a vaccine is made in the right way and the regulator confirms that the vaccine is safe will it be applied. Because there is no opportunity to compromise with security.

Post a Comment

0 Comments